Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2013.07.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study.
BMJ Open Ophthalmol
December 2024
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
Article Synopsis
- The study aimed to evaluate the feasibility of using zoledronic acid (ZA) as a supplementary treatment for neovascular age-related macular degeneration (nAMD) in a randomized controlled trial.
- A total of 40 nAMD patients were split into two groups, with one receiving ZA and the other a placebo, and the primary focus was on changes in visual acuity after treatment.
- Results showed that the group receiving ZA had improved visual acuity compared to the placebo group, suggesting potential benefits that warrant further exploration, although the small sample size limits the strength of these findings.
Atypical Presentation of Primary Hyperparathyroidism.
Cureus
November 2024
Diabetes and Endocrinology, University Hospitals Plymouth National Health Service (NHS) Trust, Plymouth, GBR.
Primary hyperparathyroidism (PHPT) typically presents with a spectrum of symptoms, including neuropsychiatric manifestations such as anxiety, depression, confusion, and, in severe cases, coma. While psychiatric symptoms are not uncommon in PHPT, acute psychosis is a rare presentation. In such cases, immediate control of serum calcium levels is crucial, and emergency parathyroidectomy may be required if medical management alone fails to control hypercalcemia.
View Article and Find Full Text PDFBackground And Aim: Hypercalcemia is one of the most common complications of advanced malignancy. Treatment of hypercalcemia among advanced cancer patients often gives rise to complex ethical issues. This study aims to explore treatment outcomes of hypercalcemia among advanced cancer patients so that palliative care physicians can design cost-effective and efficient approaches to diagnosis and treatment for these patients.
View Article and Find Full Text PDFBisphosphonate therapy for persistent hyperparathyroidism after kidney transplantation-A case report.
Nephrology (Carlton)
January 2025
Kwong Wah Hospital, Kowloon, Hong Kong.
Post-transplant hyperparathyroidism (PT-HPT) is common in kidney transplant recipients (KTRs) and can cause nephrocalcinosis and graft dysfunction. Cinacalcet is commonly used for treating PT-HPT but may induce calciuria and exacerbate nephrocalcinosis. The concurrent use of bisphosphonates with cinacalcet to prevent this complication has not been reported.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to assess how effective a gel with active oxygen is in preventing Medication-Related Osteonecrosis of the Jaw (MRONJ) in a rat model.
- - Twelve rats underwent surgery after receiving a drug (zoledronate) known to cause osteonecrosis and were divided into two groups: one treated with oxygen gel and the other left untreated.
- - Results showed that the untreated group had more severe MRONJ symptoms, suggesting that the gel may help in preventing this condition, although further research is needed due to the pilot nature of the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!